Tom Powles: 1st perioperative immune therapy study to show an OS in bladder cancer
Tom Powles shared an article on X:
“Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer.
Published in The New England Journal of Medicine.”
Tittle: Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Author: Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie,Joshua J. Meeks, Hiroyuki Nishiyama and Toan Quang Vu.
Source: Tom Powles/X
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023